Home » Stocks » ATNX

Athenex, Inc. (ATNX)

Stock Price: $3.66 USD -0.09 (-2.40%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $3.70 +0.04 (1.09%) Jul 26, 7:51 PM
Market Cap 413.54M
Revenue (ttm) 138.48M
Net Income (ttm) -151.80M
Shares Out 93.43M
EPS (ttm) -1.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $3.66
Previous Close $3.75
Change ($) -0.09
Change (%) -2.40%
Day's Open 3.77
Day's Range 3.65 - 3.82
Day's Volume 1,267,841
52-Week Range 3.65 - 15.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and Canada Athenex expands its international commercial partnerships for tirbanibulin in Australia, N...

18 hours ago - GlobeNewsWire

BUFFALO, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for th...

4 days ago - GlobeNewsWire

Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.

6 days ago - Zacks Investment Research

BUFFALO, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...

1 week ago - GlobeNewsWire

Wall Street recommends buying shares of Athenex Inc. ( ATNX , Financial) and Bellerophon Therapeutics Inc. ( BLPH , Financial). This sounds quite surprising as these two equities have performed poorly o...

Other stocks mentioned: BLPH
2 weeks ago - GuruFocus

Athenex Inc (NASDAQ: ATNX) held a Type A meeting with the FDA during the second quarter of 2021 to discuss the deficiencies raised in the Complete Response Letter (CRL) regarding application for oral pa...

2 weeks ago - Benzinga

BUFFALO, N.Y., July 06, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...

2 weeks ago - GlobeNewsWire

SAN DIEGO & BUFFALO, N.Y.--(BUSINESS WIRE)---- $ATNX #ATNX--Shareholder rights law firm Robbins LLP is investigating Athenex, Inc. (NASDAQ: ATNX) to determine whether certain Athenex officers and direct...

1 month ago - Business Wire

BUFFALO, N.Y., June 04, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...

1 month ago - GlobeNewsWire

European Commission Decision Anticipated by July 2021 European Commission Decision Anticipated by July 2021

2 months ago - GlobeNewsWire

BUFFALO, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the...

2 months ago - GlobeNewsWire

Athenex (ATNX) delivered earnings and revenue surprises of 27.03% and 110.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Athenex (NASDAQ:ATNX) moved higher by 2.2% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 12.50% over the past year to ($0.27), whi...

2 months ago - Benzinga

Plan to Request Type A Meeting with the FDA for Oral Paclitaxel by the End of May

2 months ago - GlobeNewsWire

A blockbuster acquisition could help the biotech "convert cancer into a chronic disease."

2 months ago - The Motley Fool

Athenex Inc (NASDAQ: ATNX) shares have risen during premarket trading in reaction to acquiring Kuur Therapeutics Inc, a portfolio company of IP Group plc, for $70 million upfront. Additionally, Kuur sha...

2 months ago - Benzinga

BUFFALO, N.Y., May 04, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for th...

2 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - May 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Athene...

2 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - May 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. ("Athenex"...

2 months ago - Newsfile Corp

NEW YORK, May 3, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action ...

2 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - May 2, 2021) - WHY:. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 ...

2 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 30, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Athenex, Inc.. (NASDAQ: ATNX)Sha...

2 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 30, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Athenex, Inc. (NASD...

2 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 30, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Athenex, Inc. (NASDAQ: ATNX) alleging that ...

2 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - April 30, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. ("Athen...

2 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or "the Company") (NASD...

2 months ago - Business Wire

San Francisco, California--(Newsfile Corp. - April 29, 2021) - Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now.Class Period: Aug. 7, 2019 - F...

2 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 29, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 201...

2 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - April 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. ("Athen...

2 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $ATNX #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athenex, Inc. (ATNX)

2 months ago - Business Wire

New York, New York--(Newsfile Corp. - April 29, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or "the Company"...

2 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 28, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or the "Company") (NASDAQ: ATNX) and certain o...

2 months ago - Newsfile Corp

Boston, Massachusetts--(Newsfile Corp. - April 28, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Athenex, Inc. (NASDAQ: ATNX). The c...

2 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or "the Company") (NASD...

2 months ago - Business Wire

Los Angeles, California--(Newsfile Corp. - April 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. ("Athen...

2 months ago - Newsfile Corp

San Francisco, California--(Newsfile Corp. - April 27, 2021) - Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now.Class Period: Aug. 7, 2019 - F...

2 months ago - Newsfile Corp

BUFFALO, N.Y., April 27, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for ...

2 months ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)-- #ATNX--Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against Athenex, Inc. (ATNX) and May 3 Deadline

3 months ago - Business Wire

New York, New York--(Newsfile Corp. - April 24, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 201...

3 months ago - Newsfile Corp

NEW YORK, April 23, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February ...

3 months ago - PRNewsWire

Boston, Massachusetts--(Newsfile Corp. - April 22, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Athenex, Inc. (NASDAQ: ATNX). The c...

3 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - April 22, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. ("Athen...

3 months ago - Newsfile Corp

Boston, Massachusetts--(Newsfile Corp. - April 20, 2021) - Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that it has filed a class action lawsuit o...

3 months ago - Newsfile Corp

San Francisco, California--(Newsfile Corp. - April 20, 2021) - Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. Class Period: Aug. 7, 2019 - ...

3 months ago - Newsfile Corp

Boston, Massachusetts--(Newsfile Corp. - April 20, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Athenex, Inc. (NASDAQ: ATNX). The c...

3 months ago - Newsfile Corp

LOS ANGELES, April 16, 2021 /PRNewswire/ --  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. ("Athenex" or "the Comp...

3 months ago - PRNewsWire

San Francisco, California--(Newsfile Corp. - April 14, 2021) - Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. Class Period: Aug. 7, 2019 - ...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 201...

3 months ago - Newsfile Corp

San Francisco, California--(Newsfile Corp. - April 8, 2021) -  Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. Class Period: Aug. 7, 2019 - ...

3 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)-- #ATNX--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 20...

3 months ago - Business Wire

About ATNX

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer d... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jun 14, 2017
CEO
Johnson Lau
Employees
593
Stock Exchange
NASDAQ
Ticker Symbol
ATNX
Full Company Profile

Financial Performance

In 2020, Athenex's revenue was $144.39 million, an increase of 42.64% compared to the previous year's $101.23 million. Losses were -$146.18 million, 18.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Athenex stock is "Buy." The 12-month stock price forecast is 9.75, which is an increase of 166.39% from the latest price.

Price Target
$9.75
(166.39% upside)
Analyst Consensus: Buy